Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OXiGENE OXGN

Healthcare Biotechnology
"OxiGene Inc is a biopharmaceutical company. The Company is engaged in the development of vascular disrupting agents, or VDAs, for the treatment of cancer. It is currently developing two clinical stage investigational drugs, both VDAs- CA4P and OXi4503."

Recent & Breaking News (NDAQ:OXGN)

UPDATE -- Mateon Therapeutics to Present New Improved Survival Outcomes for CA4P in Recurrent Ovarian Cancer at June 27 Investor Event

GlobeNewswire June 20, 2016

OXiGENE Announces Name Change to Mateon Therapeutics

GlobeNewswire June 17, 2016

OXiGENE Receives U.S. Orphan Drug Designation for CA4P to Treat Glioma

GlobeNewswire June 10, 2016

OXiGENE Announces Results of Phase 2 Study of CA4P in Recurrent Ovarian Cancer Published in Journal of Clinical Oncology

GlobeNewswire May 24, 2016

Cynapsus Therapeutics Appoints Frederick Driscoll to Its Board of Directors

GlobeNewswire May 20, 2016

OXiGENE Reports First Quarter 2016 Financial Results

GlobeNewswire May 9, 2016

Oxigene Receives Fast Track Designation From U.S. FDA for CA4P

GlobeNewswire March 30, 2016

OXiGENE Reports 2015 Financial Results

GlobeNewswire March 28, 2016

OXiGENE Receives European Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors

GlobeNewswire March 25, 2016

OXiGENE Appoints Dr. Simon Pedder to Board of Directors

GlobeNewswire March 24, 2016

LifeSci Capital Initiates Coverage of OXiGENE

Accesswire March 3, 2016

OXiGENE Announces Upcoming Presentation at the BIO-CEO Conference and Provides Business Update

GlobeNewswire February 3, 2016

OXiGENE Receives U.S. Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors

GlobeNewswire January 6, 2016

OXiGENE Receives European Orphan Drug Designation for OXi4503 to Treat Acute Myeloid Leukemia

GlobeNewswire December 17, 2015

OXiGENE Reports Third Quarter 2015 Financial Results

GlobeNewswire November 10, 2015

OXiGENE Announces Positive Initial Data From Phase 1b Study of CA4P in Combination With Pazopanib in Patients With Advanced Recurrent Ovarian Cancer

GlobeNewswire November 5, 2015

OXiGENE Announces Initiation of Phase 1b/2 Clinical Trial of OXi4503 in Acute Myeloid Leukemia

GlobeNewswire October 21, 2015

OXiGENE Announces Interim Phase 2 Data for Lead Clinical Candidate CA4P (fosbretabulin) in Neuroendocrine Tumors

GlobeNewswire October 19, 2015

OXiGENE to Present at the 14th Annual BIO Investor Forum

GlobeNewswire October 16, 2015

OXiGENE Announces Plans to Advance CA4P (Fosbretabulin) in Two Late-Stage Clinical Trials

GlobeNewswire September 29, 2015